ANDA 219386, held by Hetero Labs Ltd Unit Iii. Suvorexant.
As of Nov 16, 2026, ANDA 219386 (Suvorexant), held by Hetero Labs Ltd Unit Iii, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 22, 2025 | Original application | Tentative approval | None posted |
| Suvorexant5MG · tablet | Suvorexant | None (tentative approval) |
| Suvorexant10MG · tablet | Suvorexant | None (tentative approval) |
| Suvorexant15MG · tablet | Suvorexant | None (tentative approval) |
| Suvorexant20MG · tablet | Suvorexant | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters